Goldman Sachs

Legence (LGN) successfully completed its IPO on September 12, 2025, offering 26 million Class A shares at $28 per share. Underwriters exercised part of their option, purchasing an additional 3.48 million shares. The IPO, led by Goldman Sachs and Jefferies, generated approximately $780.2 million in net proceeds. Legence plans to use these funds to repay term loan debt and for general corporate purposes, aiming for stable growth and long-term value creation.

Goldman Sachs and T. Rowe Price are collaborating to expand access to public and private market investments, primarily targeting retirement and wealth channels. Goldman Sachs will invest up to $1 billion in T. Rowe Price common stock. The partnership will focus on co-branded target-date strategies, model portfolios, and multi-asset offerings, leveraging Goldman’s expertise in alternative investments and T. Rowe Price’s retirement leadership. The goal is to provide a broader range of investors, including individuals and advisors, with diversified investment solutions and personalized advice.

Charter Communications (CHTR) President and CEO Christopher Winfrey will present at the Goldman Sachs Communacopia + Technology Conference on September 9, 2025. His presentation, starting at 10:50 a.m. PT, is expected to cover Charter’s strategic direction in the competitive broadband market. Charter provides services to over 57 million homes and businesses via its Spectrum brand. A live webcast will be available on Charter’s investor relations website, ir.charter.com.

Kemper Corporation (KMPR) announced a $150 million accelerated share repurchase (ASR) agreement with Goldman Sachs, part of its $550 million authorization. The insurer believes shares are undervalued and the ASR demonstrates confidence in its business. Kemper will pay Goldman Sachs $150 million on August 14, 2025, receiving an initial 2,279,203 shares. The final number depends on the volume-weighted average price of Kemper’s stock. The ASR is expected to conclude within three months. Kemper is a specialized insurer with $13 billion in assets, serving 4.7 million policies.

Bicara Therapeutics (BCAX) will present at the Goldman Sachs 46th Annual Global Healthcare Conference. Management will host a fireside chat on June 10th to discuss the company’s strategy and pipeline. The presentation will focus on their clinical-stage bifunctional therapies, particularly their lead program, ficerafusp alfa, designed to treat solid tumors by overcoming challenges in the tumor microenvironment. A webcast replay will be available.